SUPN Q3 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$176M+14.2% YoY

Gross Profit

$158M90.0% margin

Operating Income

$41M23.2% margin

Net Income

$38M21.9% margin

EPS (Diluted)

$0.69

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$53M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$336M

Stockholders' Equity

$1.0B

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$176M	$154M	+14.2%
Gross Profit	$158M	$134M	+17.7%
Operating Income	$41M	$8M	+401.9%
Net Income	$38M	-$16M	+341.0%

Revenue Segments

Product

$170M49%

Qelbree

$62M18%

GOCOVRI

$36M10%

Oxtellar X R

$30M9%

APOKYN

$20M6%

Trokendi Xr

$15M4%

Manufactured Product, Other

$7M2%

Royalty, License And Other Revenue

$5M2%